Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Six

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Journal of Medicinal Chemistry|April 28, 2006
Differential inhibition of group IVA and group VIA phospholipases A2 by 2-oxoamidesDaren Stephens, Efrosini Barbayianni, Violetta Constantinou-Kokotou, et al.
Journal of Medicinal Chemistry|June 25, 2004
Inhibition of group IVA cytosolic phospholipase A2 by novel 2-oxoamides in vitro, in cells, and in vivoGeorge Kokotos, David A Six, Vassilios Loukas, et al.
The Journal of Antimicrobial Chemotherapy|September 17, 2024
Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22James A Karlowsky, Mark G Wise, Meredith A Hackel, et al.
Biochemistry|March 5, 2009
Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxCAdam W Barb, Tanya M Leavy, Lori I Robins, et al.
Antimicrobial Agents and Chemotherapy|April 1, 2025
Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic <i>Escherichia coli</i> strainsTsuyoshi Uehara, Cassandra L Chatwin, Brittany Miller, et al.
Acta Cardiologica|May 13, 2005
Percutaneous transcatheter closure of atrial septal defects: initial single-centre experience and follow-up results. Initial experience with three-dimensional echocardiographySerge De Ridder, Maarten-Jan Suttorp, Sjef M P G Ernst, et al.
Antimicrobial Agents and Chemotherapy|December 21, 2022
<i>In Vitro</i> Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) ProgramJames A Karlowsky, Meredith A Hackel, Mark G Wise, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2025
Structure and mechanism of taniborbactam inhibition of the cefepime-hydrolyzing, partial R2-loop deletion <i>Pseudomonas</i>-derived cephalosporinase variant PDC-88Andrew R Mack, Vijay Kumar, Christopher R Bethel, et al.
Carbohydrate Polymers|July 24, 2024
From raw microalgae to bioplastics: Conversion of Chlorella vulgaris starch granules into thermoplastic starchA Six, D Dauvillée, C Lancelon-Pin, et al.
Journal of Medicinal Chemistry|August 4, 2007
Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group V secreted phospholipase A2David A Six, Efrosini Barbayianni, Vassilios Loukas, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Journal of Medicinal Chemistry|April 28, 2006
Differential inhibition of group IVA and group VIA phospholipases A2 by 2-oxoamidesDaren Stephens, Efrosini Barbayianni, Violetta Constantinou-Kokotou, et al.
Journal of Medicinal Chemistry|June 25, 2004
Inhibition of group IVA cytosolic phospholipase A2 by novel 2-oxoamides in vitro, in cells, and in vivoGeorge Kokotos, David A Six, Vassilios Loukas, et al.
The Journal of Antimicrobial Chemotherapy|September 17, 2024
Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22James A Karlowsky, Mark G Wise, Meredith A Hackel, et al.
Biochemistry|March 5, 2009
Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxCAdam W Barb, Tanya M Leavy, Lori I Robins, et al.
Antimicrobial Agents and Chemotherapy|April 1, 2025
Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic <i>Escherichia coli</i> strainsTsuyoshi Uehara, Cassandra L Chatwin, Brittany Miller, et al.
Acta Cardiologica|May 13, 2005
Percutaneous transcatheter closure of atrial septal defects: initial single-centre experience and follow-up results. Initial experience with three-dimensional echocardiographySerge De Ridder, Maarten-Jan Suttorp, Sjef M P G Ernst, et al.
Antimicrobial Agents and Chemotherapy|December 21, 2022
<i>In Vitro</i> Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) ProgramJames A Karlowsky, Meredith A Hackel, Mark G Wise, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2025
Structure and mechanism of taniborbactam inhibition of the cefepime-hydrolyzing, partial R2-loop deletion <i>Pseudomonas</i>-derived cephalosporinase variant PDC-88Andrew R Mack, Vijay Kumar, Christopher R Bethel, et al.
Carbohydrate Polymers|July 24, 2024
From raw microalgae to bioplastics: Conversion of Chlorella vulgaris starch granules into thermoplastic starchA Six, D Dauvillée, C Lancelon-Pin, et al.
Journal of Medicinal Chemistry|August 4, 2007
Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group V secreted phospholipase A2David A Six, Efrosini Barbayianni, Vassilios Loukas, et al.
Pageof 9